161 related articles for article (PubMed ID: 24957772)
1. Glycomic expression in esophageal disease.
Mohanty S; Tsiouris A; Hammoud Z
Metabolites; 2012 Nov; 2(4):1004-11. PubMed ID: 24957772
[TBL] [Abstract][Full Text] [Related]
2. Comparative glycomic profiling in esophageal adenocarcinoma.
Hammoud ZT; Mechref Y; Hussein A; Bekesova S; Zhang M; Kesler KA; Novotny MV
J Thorac Cardiovasc Surg; 2010 May; 139(5):1216-23. PubMed ID: 20412957
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
4. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
5. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
Beilstein M; Silberg D
Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review.
Luigiano C; Iabichino G; Eusebi LH; Arena M; Consolo P; Morace C; Opocher E; Mangiavillano B
Gastroenterol Res Pract; 2016; 2016():4249510. PubMed ID: 28070182
[TBL] [Abstract][Full Text] [Related]
10. Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
Wolfsen HC
J Clin Gastroenterol; 2005 Mar; 39(3):189-202. PubMed ID: 15718860
[TBL] [Abstract][Full Text] [Related]
11. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
12. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
13. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
14. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
[TBL] [Abstract][Full Text] [Related]
16. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
17. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
[TBL] [Abstract][Full Text] [Related]
19. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
